Tag : CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

CONFERENCE UPDATE

Dupilumab reduces the use of OCS and antibiotics in patients with CRSwNP in real-world practice
Dupilumab is indicated as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). It has been shown to improve both objective and patient-reported outcomes in this population.
CONFERENCE UPDATE

Symptom reduction and QoL improvement in CRSwNP patients with mepolizumab: Results from the phase 3 SYNAPSE trial
Chronic rhinosinusitis with nasal polyp (CRSwNP) is a chronic disease characterized by elevated interleukin 5 (IL-5) levels and is often associated with severe sinonasal symptoms and nasal obstruction. Mepolizumab is a humanized anti-IL-5 antibody approved as an add-on medication for CRSwNP. In the pivotal phase 3 SYNAPSE study, mepolizumab demonstrated improvement in sinonasal outcomes and reduction in corticosteroid use or surgery need in patients with CRSwNP. However, its effect on the number of low-symptom/symptom-free or symptom-reduced days remained unclear.